menu
    • menu

    Company profile for Crystalys Therapeutics

    NEW Drugs in Dev: 1
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Crystalys is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of gout. Backed by Novo Holdings and Catalys Pacific, our team combines world-class expertise in gout drug development with a mission to deliver safer, more effective therapies. Our lead candidate, Dotinurad, a next-generation URAT1 inhibitor with best-in-class potential, is advancing into global Phase 3 trials as a second-line ther...
    Crystalys is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of gout. Backed by Novo Holdings and Catalys Pacific, our team combines world-class expertise in gout drug development with a mission to deliver safer, more effective therapies. Our lead candidate, Dotinurad, a next-generation URAT1 inhibitor with best-in-class potential, is advancing into global Phase 3 trials as a second-line therapy, supported by extensive clinical data from approvals in multiple Asian markets.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Crystalys TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12544 High Bluff Dr., #310 San Diego, CA 92130
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://crystalystx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/crystalys-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crystalys Therapeutics Expands Phase 3 RUBY Study In Europe
    Crystalys Therapeutics Expands Phase 3 RUBY Study In Europe

    02 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-phase-3-ruby-study-with-first-patients-dosed-at-european-sites-302674720.html

    PR NEWSWIRE
    02 Feb 2026
    Share Share
    Crystalys Therapeutics Names Thacker CFO for Dotinurad Phase 3
    Crystalys Therapeutics Names Thacker CFO for Dotinurad Phase 3

    21 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-leadership-team-with-appointment-of-justin-thacker-as-chief-financial-officer-to-support-advancement-of-phase-3-trials-of-dotinurad-302665997.html

    PR NEWSWIRE
    21 Jan 2026
    Share Share
    Addition Debuts $100M Fund for Rare Disease One-Time Therapies
    Addition Debuts $100M Fund for Rare Disease One-Time Therapies

    17 Dec 2025

    // BIOSPACE

    https://www.biospace.com/business/addition-debuts-with-100m-to-advance-one-time-therapies-for-rare-chronic-diseases

    BIOSPACE
    17 Dec 2025
    Share Share
    Crystalys Therapeutics Progresses Dotinurad Phase 3 Trials
    Crystalys Therapeutics Progresses Dotinurad Phase 3 Trials

    21 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/crystalys-therapeutics-advances-phase-3-trials-of-dotinurad-for-the-treatment-of-gout-with-dosing-of-first-patients-302589382.html

    PR NEWSWIRE
    21 Oct 2025
    Share Share
    Fortress, Urica Dose First Patients In Ph3 Dotinurad Gout Trial
    Fortress, Urica Dose First Patients In Ph3 Dotinurad Gout Trial

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3170212/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-First-Patients-Dosed-in-Crystalys-Therapeutics-Global-Phase-3-Trials-of-Dotinurad-for-the-Treatment-of-Gout.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    Fortress Biotech And Urica Therapeutics Unveil Crystalys
    Fortress Biotech And Urica Therapeutics Unveil Crystalys

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159491/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-Crystalys-Therapeutics-205-Million-Series-A-Financing.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search